Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 11/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14198825 | 0.81 | IDO1 (0.46) | MAOB | |
| SCHEMBL20529938 | 0.79 | PTGS2 (0.54) | PTGS2PTGS1 | |
| SCHEMBL8442546 | 0.73 | MAPK14 (0.49) | MAPK14PTGS2PTGS1HTTNR3C2 | |
| SCHEMBL20529853 | 0.72 | PTGS1 (0.54) | PTGS2PTGS1MAOB | |
| SCHEMBL21113587 | 0.71 | PTGS2 (0.62) | PTGS2PTGS1 | |
| SCHEMBL8389316 | 0.71 | MAPK14 (0.64) | MAPK14PTGS2PTGS1HTTNR3C2 | |
| SCHEMBL21113575 | 0.70 | PTGS1 (0.38) | PTGS2PTGS1MAOB | |
| SCHEMBL5694270 | 0.70 | MAPK14 (0.62) | MAPK14PTGS2PTGS1HTTNR3C2 | |
| SCHEMBL8266062 | 0.70 | MAPK14 (0.62) | MAPK14PTGS2PTGS1 | |
| SCHEMBL28997882 | 0.69 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1767835-A | Compositions comprising cyclooxygenase-2 selective inhibitors and glucosamine for the treatment and prevention of pain and inflammation | PHARMACIA CORP (US) | 2006-05-03 | — | — | CN | claimed |
| CN-1241567-C | Synergistic analgestic combination of opioid analgsic and cyclooxygenase-2 | EURO CELTIQUE SA (LU) | 2006-02-15 | — | — | CN | claimed |
| CN-1697654-A | Use of COx-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections | UPJOHN CO (US) | 2005-11-16 | — | — | CN | claimed |
| CN-1575182-A | Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate | PHARMACIA CORP (US) | 2005-02-02 | — | — | CN | claimed |
| CN-1561246-A | Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease | PHARMACIA CORP (US) | 2005-01-05 | — | — | CN | claimed |
| CN-1527709-A | Therapeutic combination for cardiovascular and inflammatory indications | — | 2004-09-08 | — | — | CN | claimed |
| CN-1371286-A | Use of cyclooxygenase-2 inhibitor matrix metallappoteinase inhibitor antineoplastic agent and optionally radiation as combination treatment of neoplasia | SEARLE & CO (US) | 2002-09-25 | — | — | CN | claimed |
| CN-1346282-A | Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as combination therapy method in treating neoplasia | SEARLE & CO (US) | 2002-04-24 | — | — | CN | claimed |
| EP-3509604-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | Trustees of Tufts College (US) | 2019-07-17 | — | — | EP | disclosed |
| WO-2018049027-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE (US) | 2018-03-15 | — | — | WO | disclosed |
| CN-100372539-C | Pharmaceutical composition comprising a combination of a bisphosphonate, a COX-2 inhibitor and paclitaxel for the treatment of malignancies | NOVARTIS AG (CH) | 2008-03-05 | — | — | CN | disclosed |
| CN-1771034-A | Combinations of peroxisome proliferators-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor | PHARMACIA CORP (US) | 2006-05-10 | — | — | CN | disclosed |
| CN-1767835-A | Compositions comprising cyclooxygenase-2 selective inhibitors and glucosamine for the treatment and prevention of pain and inflammation | PHARMACIA CORP (US) | 2006-05-03 | — | — | CN | disclosed |
| CN-1241567-C | Synergistic analgestic combination of opioid analgsic and cyclooxygenase-2 | EURO CELTIQUE SA (LU) | 2006-02-15 | — | — | CN | disclosed |
| CN-1697654-A | Use of COx-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections | UPJOHN CO (US) | 2005-11-16 | — | — | CN | disclosed |
| CN-1642544-A | Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors | PHARMACIA CORP (US) | 2005-07-20 | — | — | CN | disclosed |
| CN-1638760-A | Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin | PHARMACIA CORP (US) | 2005-07-13 | — | — | CN | disclosed |
| CN-1638759-A | Pharmaceutical composition comprising a bisphosphonate and a COX-2 inhibitor for the treatment of bone diseases | NOVARTIS AG (CH) | 2005-07-13 | — | — | CN | disclosed |
| CN-1575182-A | Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate | PHARMACIA CORP (US) | 2005-02-02 | — | — | CN | disclosed |
| CN-1561246-A | Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease | PHARMACIA CORP (US) | 2005-01-05 | — | — | CN | disclosed |